Idorsia Company Profile
✉ Email this page to a colleague
What is the competitive landscape for IDORSIA, and when can generic versions of IDORSIA drugs launch?
IDORSIA has two approved drugs.
There are eight US patents protecting IDORSIA drugs.
There are one hundred and forty-eight patent family members on IDORSIA drugs in thirty-six countries and twelve supplementary protection certificates in eleven countries.
Summary for Idorsia
| International Patents: | 148 |
| US Patents: | 8 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Idorsia
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-002 | Apr 7, 2022 | RX | Yes | Yes | 9,732,075 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-001 | Apr 7, 2022 | RX | Yes | No | 9,790,208 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-002 | Apr 7, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Idorsia | TRYVIO | aprocitentan | TABLET;ORAL | 217686-001 | Mar 19, 2024 | RX | Yes | Yes | 10,919,881 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-002 | Apr 7, 2022 | RX | Yes | Yes | 10,023,560 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Idorsia | QUVIVIQ | daridorexant hydrochloride | TABLET;ORAL | 214985-001 | Apr 7, 2022 | RX | Yes | No | 10,023,560 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Idorsia | TRYVIO | aprocitentan | TABLET;ORAL | 217686-001 | Mar 19, 2024 | RX | Yes | Yes | 11,787,782 | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Idorsia Drugs
Supplementary Protection Certificates for Idorsia Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2855453 | LUC00279 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: DARIDOREXANT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE CHLORHYDRATE DE DARIDOREXANT; AUTHORISATION NUMBER AND DATE: EU 1/22/1638 20220502 |
| 2855453 | 2022C/543 | Belgium | ⤷ Sign Up | PRODUCT NAME: DARIDOREXANT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE CHLORHYDRATE DE DARIDOREXANT; AUTHORISATION NUMBER AND DATE: EU/1/22/1638 20220502 |
| 2855453 | C02855453/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: DARIDOREXANTUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68481 01.12.2022 |
| 2855453 | CA 2022 00041 | Denmark | ⤷ Sign Up | PRODUCT NAME: DARIDOREXANT OG FARMACEUTISK ACCEPTABLE SALTE HERAF, SAERLIGT DARIDOREXANT HYDROCHLORID; REG. NO/DATE: EU/1/22/1638 20220502 |
| 2855453 | 301197 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DARIDOREXANT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER DARIDOREXANTHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/22/1638 20220502 |
| 2855453 | C202230046 | Spain | ⤷ Sign Up | PRODUCT NAME: DARIDOREXANT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR DARIDOREXANT HIDROCLORURO; NATIONAL AUTHORISATION NUMBER: EU/1/22/1638; DATE OF AUTHORISATION: 20220429; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1638; DATE OF FIRST AUTHORISATION IN EEA: 20220429 |
| 2855453 | CR 2022 00041 | Denmark | ⤷ Sign Up | PRODUCT NAME: DARIDOREXANT OG FARMACEUTISK ACCEPTABLE SALTE HERAF, SAERLIGT DARIDOREXANT HYDROCHLORID; REG. NO/DATE: EU/1/22/1638 20220502 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
